Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington; Department of Pediatrics, University of Washington, Seattle, Washington; Pediatric Infectious Diseases Division, Seattle Children's Hospital, Seattle, Washington.
Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington.
Biol Blood Marrow Transplant. 2018 Oct;24(10):2160-2163. doi: 10.1016/j.bbmt.2018.07.006. Epub 2018 Aug 7.
Recent data suggest human rhinovirus (HRV) is associated with lower respiratory tract infection and mortality in hematopoietic cell transplant (HCT) recipients. Examining risk factors for prolonged viral shedding may provide critical insight for the development of novel therapeutics and help inform infection prevention practices. Our objective was to identify risk factors for prolonged shedding of HRV post-HCT. We prospectively collected weekly nasal samples from allogeneic HCT recipients from day 0 to day 100 post-transplant, and performed real-time reverse transcriptase PCR (December 2005 to February 2010). Subjects with symptomatic HRV infection and a negative test within 2 weeks of the last positive were included. Duration of shedding was defined as time between the first positive and first negative samples. Cycle threshold (Ct) values were used as a proxy for viral load. HRV species were identified by sequencing the 5' noncoding region. Logistic regression analyses were performed to evaluate factors associated with prolonged shedding (≥21 days). We identified 38 HCT recipients with HRV infection fulfilling study criteria (32 adults, 6 children). Median duration of shedding was 9.5 days (range, 2 to 89 days); 18 patients had prolonged shedding. Among 26 samples sequenced, 69% were species A, and species B and C accounted for 15% each; the median shedding duration of HRV did not differ among species (P = .17). Bivariable logistic regression analyses suggest that initial high viral load (low Ct value) is associated with prolonged shedding. HCT recipients with initial high viral loads are at risk for prolonged HRV viral shedding.
最近的数据表明,人类鼻病毒(HRV)与造血细胞移植(HCT)受者的下呼吸道感染和死亡率有关。研究延长病毒脱落的危险因素可能为新型治疗药物的开发提供重要的见解,并有助于了解感染预防措施。我们的目的是确定 HCT 后 HRV 延长脱落的危险因素。我们前瞻性地收集了所有异体 HCT 受者从移植后第 0 天到第 100 天的每周鼻样本,并进行了实时逆转录 PCR(2005 年 12 月至 2010 年 2 月)。将有症状的 HRV 感染且最后一次阳性后 2 周内阴性的患者纳入研究。脱落持续时间定义为首次阳性和首次阴性样本之间的时间。循环阈值(Ct)值用作病毒载量的替代指标。通过测序 5'非编码区鉴定 HRV 种。采用逻辑回归分析评估与延长脱落(≥21 天)相关的因素。我们确定了 38 名符合研究标准的 HRV 感染 HCT 受者(32 名成人,6 名儿童)。脱落持续时间中位数为 9.5 天(范围 2 至 89 天);18 名患者有延长脱落。在 26 个测序样本中,69%为 A 种,B 种和 C 种各占 15%;HRV 的脱落持续时间在种间无差异(P = .17)。双变量逻辑回归分析表明,初始高病毒载量(低 Ct 值)与延长脱落有关。初始病毒载量高的 HCT 受者有延长 HRV 病毒脱落的风险。